Imatinib in the treatment of chronic myeloid leukemia: current perspectives on optimal dose

Joanna Waclaw,1 Tomasz Sacha,1 Tomasz Stoklosa,21Department of Hematology, Jagiellonian University Collegium Medicum, Kraków, 2Department of Immunology, Medical University of Warsaw, Warsaw, Poland Abstract: Imatinib was the first tyrosine kinase inhibitor (TKI), successfully used in a c...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Waclaw J, Sacha T, Stoklosa T
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://doaj.org/article/9962693a876d47368bf62bed7aa6b1bc
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares